×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

EU approves marketing of dupilumab for atopic dermatitis

  484 Views

eMediNexus    02 October 2017

The European Commission has granted marketing authorization to dupilumab (Dupixent, Samofi and Regeneron), a human monoclonal antibody, for adults with moderate to severe atopic dermatitis, to be used with or without topical corticosteroids. Dupilumab will be available in a premixed syringe for biweekly injection.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.